4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Enliven Therapeutics, Inc. (ELVN) operates in the Biotechnology industry and is headquartered in Boulder, United States with about 61 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, ELVN reported $0M in revenue and ($104M) in net income.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($120M) | ($105M) | ($84M) | ($39M) |
| Net Income | ($104M) | ($89M) | ($72M) | ($38M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($28M) | ($34M) | ($25M) | ($29M) | ($32M) | — |
| Net Income | ($24M) | ($30M) | ($20M) | ($25M) | ($28M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $476M | $326M | $272M | $83M | — |
| Total Liabilities | $17M | $16M | $26M | $160M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ELVN viewer.
About TickerBase · Data methodology & sources